- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Apnimed, a company based in Massachusetts, is seeking FDA approval for its drug candidates targeting the OSA market and is also planning an IPO to fund operations.
1 report, 1 independent
Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Apnimed, a company based in Massachusetts, is seeking FDA approval for its drug candidates targeting the OSA market and is also planning an IPO to fund operations.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
Coverage
Newest first; wire copies grouped- yahoo.comApnimed scouts $160m IPO to back late-stage sleep apnoea pill development